Edgewise Therapeutics (EWTX) Current Leases (2022 - 2026)

Edgewise Therapeutics has reported Current Leases for 5 years, with the latest figure at $1.0 million in Q1 2026.

• Quarterly Current Leases rose 1.6% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 1.6% YoY) and the FY2025 annual result came in at $1.0 million, up 1.81% from the prior year.
• Current Leases was little changed at $1.0 million in Q1 2026 per EWTX's latest filing, from $1.0 million in the prior quarter.
• Over five years, Current Leases peaked at $1.0 million in Q1 2026 and troughed at $104000.0 in Q2 2022.
• A 5-year average of $844062.5 and a median of $986000.0 in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2026: Current Leases surged 738.46% in 2023, then gained 1.6% in 2026.
• Over 5 years, Current Leases stood at $608000.0 in 2022, then surged by 61.18% to $980000.0 in 2023, then increased by 1.63% to $996000.0 in 2024, then grew by 1.81% to $1.0 million in 2025, then gained by 0.3% to $1.0 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.0 million, $1.0 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.